Land: Vereinigte Staaten
Sprache: Englisch
Quelle: NLM (National Library of Medicine)
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR), SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F) (PHOSPHATE ION - UNII:NK08V8K8HR)
Fresenius Kabi USA, LLC
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 276 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Sodium Phosphates Injection, USP is indicated as a source of phosphate, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions. Sodium phosphate is contraindicated in diseases where high phosphate or low calcium levels may be encountered, and in patients with hypernatremia.
These vials are flip-top, Single Dose Vials, packaged 25 vials per tray. The vials marked with ‘‘PX’’ are partially filled to facilitate transfer of the contents. Do not administer unless solution is clear and seal intact. Discard unused portion. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
unapproved drug other
SODIUM PHOSPHATES - SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE INJECTION, SOLUTION FRESENIUS KABI USA, LLC _Disclaimer: This drug has not been found by FDA to be safe and effective, and this_ _labeling has not been approved by FDA. For further information about unapproved_ _drugs, click here._ ---------- SODIUM PHOSPHATES INJECTION USP _3 mmol P and 4 mEq Na_ / _mL_ _FOR ADDITIVE USE ONLY AFTER DILUTION IN IV FLUIDS_ DESCRIPTION Sodium Phosphates Injection, USP, 3 mmol/mL (millimoles/mL), is a sterile, nonpyrogenic, _concentrated solution _containing a mixture of monobasic sodium phosphate and dibasic sodium phosphate in Water for Injection. The solution is administered after dilution by the intravenous route as an electrolyte replenisher. _It must not be administered undiluted._ Each mL contains: Monobasic sodium phosphate, monohydrate, 276 mg; dibasic sodium phosphate, anhydrous, 142 mg (equivalent to dibasic sodium phosphate, heptahydrate, 268 mg); Water for Injection q.s. In the 5 mL and 15 mL product, phosphoric acid and/or NaOH may have been added for pH adjustment. Each mL provides 3 mmol of phosphorus and 4 mEq sodium. It contains no bacteriostat, antimicrobial agent or added buffer. The pH is 5.7 (approx.). The osmolar concentration is 7 mOsmol/mL (calc.) The solution is intended as an alternative to potassium phosphate to provide phosphate ion (PO ) for addition to large volume infusion fluids for intravenous use. Sodium Phosphates, USP, monohydrate monobasic is chemically designated NaH PO • H O. Occurs as white, odorless crystals or granules freely soluble in water. Dibasic Sodium Phosphate, USP, anhydrous, is chemically designated Na HPO . Occurs as a colorless or white granular salt freely soluble in water. CLINICAL PHARMACOLOGY Phosphorus in the form of organic and inorganic phosphate has a variety of important biochemical functions in the body and is involved in many significant metabolic and enzyme reactions in almost all organs and tissues. It exerts a modifying influence on the steady state of Lesen Sie das vollständige Dokument